Clavis has announced positive final results from a phase-II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML).
Elacytarabine is a novel cytotoxic agent for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents.
In the phase-II study, 61 patients with late stage AML who failed to respond or relapsed after two separate rounds of treatments, received third-line therapy (also called second salvage) with intravenous elacytarabine.
Geir Christian Melen, CEO of Clavis, said: “We are encouraged by the positive results from this elacytarabine Phase II study in AML, particularly as this is a very difficult patient population to treat.”
“The results represent a clinical proof of concept for elacytarabine as an improved treatment for AML and also validate the potential of our Lipid Vector Technology to produce cancer drugs with enhanced performance. We look forward to continuing the development of elacytarabine, and commencing potential registration trials,” he added.